BioNTech and Pfizer received U.S. FDA approval for their 2026-2027 COVID-19 Vaccine formula targeting the XFG variant, with shipping beginning immediately. The authorization covers adults ages 65 years and older and higher-risk individuals ages 5 through 64, supporting near-term availability in U.S. pharmacies, hospitals and clinics.

Key Highlights

  • Doses are expected to reach U.S. pharmacies, hospitals and clinics in the coming days.
  • More than five billion COMIRNATY doses have been distributed globally to date.
  • Shipping of the 2026-2027 vaccine begins immediately.

Availability is expected in U.S. pharmacies, hospitals and clinics in the coming days.

XFG Vaccine Clears FDA Review

The authorization rests on clinical, non-clinical and real-world evidence previously submitted by BioNTech (NASDAQ: BNTX) and Pfizer. Manufacturing and quality information, together with non-clinical data, showed that the XFG-adapted vaccine generated strong immune responses against XFG and other contemporary SARS-CoV-2 lineages.

The approval applies to the specified age groups and higher-risk population.

Immediate U.S. Distribution

Shipping of the 2026-2027 vaccine begins immediately. The companies said doses will become available across the United States through pharmacies, hospitals and clinics in the coming days.

The formula was selected for the fall 2026 U.S. vaccination season. BioNTech and Pfizer said the updated vaccine targets XFG in line with the FDA’s guidance on matching contemporary circulating variants.

Global Dose Distribution

BioNTech’s forward-looking statements include expectations regarding manufacturing, distribution and supply, along with anticipated changes in COVID-19 vaccine demand. The companies also identified future Demand for initial or booster doses as an area of uncertainty.

Peers Moving on This News

Source(s)

  • https://www.sec.gov/Archives/edgar/data/1776985/000177698526000059/form6-kxfgvariantvaccinefd.htm